Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




May
17
Today In Oncology
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC
Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study
Early Ovarian Cancer Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival
Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer
Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo